Loading...
•
Mar 31, 2024
Treace Q1 2024 Earnings Report
Reported financial results for the first quarter ended March 31, 2024.
Key Takeaways
Treace Medical Concepts reported a 21% increase in revenue to $51.1 million for Q1 2024 compared to the same period in 2023. The company's gross margin was 80.2%. Net loss attributable to common stockholders was ($18.7) million, and the Adjusted EBITDA loss improved to ($8.3) million.
Revenue of $51.1 million in first quarter 2024 increased 21% over same period in 2023
Gross margin of 80.2% in first quarter 2024
First quarter 2024 net loss attributable to common stockholders was ($18.7) million compared to ($13.5) million for same period in 2023
Adjusted EBITDA loss improved to ($8.3) million in first quarter 2024 compared to loss of ($10.0) million for same period in 2023
Forward Guidance
The Company now expects full-year 2024 revenue of $201 million to $211 million, representing growth of 7% to 13%, compared to full-year 2023. The Company continues to expect to make significant improvement in Adjusted EBITDA for full-year 2024 and anticipates Adjusted EBITDA to improve approximately 50% compared to full-year 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...